adafosbuvir (AL-335) / Medivir, J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
adafosbuvir (AL-335) / J&J, Medivir
NCT02765490 / 2015-004200-38: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Checkmark Initiation of enrollment in P2b OMEGA-1 trial in HCV patients
Nov 2016 - Nov 2016: Initiation of enrollment in P2b OMEGA-1 trial in HCV patients
Checkmark P2b study of AL-335, ACH-3102 and Simeprevir
Nov 2016 - Nov 2016: P2b study of AL-335, ACH-3102 and Simeprevir
Checkmark For odalasvir, AL-335, and simeprevir for genotype 1 treatment-naive HCV
More
Completed
2b
365
Europe, Canada, RoW
AL-335, Odalasvir, Simeprevir
Janssen Research & Development, LLC
Hepatitis C, Chronic
08/17
11/17
NCT02993250: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Completed
2a
33
Japan
AL-335, JNJ-64146212, Odalasvir (ODV), JNJ-64289901, Simeprevir (SMV), TMC435
Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
05/18
05/18
NCT02569710 / 2016-002845-46: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Hourglass Sep 2016 - Sep 2016 : Interim data from trial of simeprevir in combination with odalasvir and AL-335 for hep-C infection at EASL-AASLD
Checkmark Interim results of hepatitisC infection
Sep 2016 - Sep 2016: Interim results of hepatitisC infection
Completed
2a
161
Europe, RoW
AL-335, Odalasvir (ODV), ACH-3102, Simeprevir (SMV)
Alios Biopharma Inc.
Chronic Hepatitis C
05/18
05/18

Download Options